메뉴 건너뛰기




Volumn 72, Issue 4, 2013, Pages 825-835

Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients

Author keywords

Polymorphism; Renal cell carcinoma; Sunitinib; Toxicity

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CD135 ANTIGEN; CYTOCHROME P450 1A1; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN RET; SUNITINIB; VASCULOTROPIN RECEPTOR 2;

EID: 84885386248     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2258-y     Document Type: Article
Times cited : (60)

References (37)
  • 4
    • 77954024679 scopus 로고    scopus 로고
    • An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma
    • 10.1016/S1359-6349(09)71451-X
    • Lee SCH, Mainwaring P, Ng C, Chang JWC, Kwong P et al (2009) An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma. Eur J Cancer Suppl (abstract) 7:428
    • (2009) Eur J Cancer Suppl (Abstract) , vol.7 , pp. 428
    • Lee, S.C.H.1    Mainwaring, P.2    Ng, C.3    Chang, J.W.C.4    Kwong, P.5
  • 6
    • 79961102885 scopus 로고    scopus 로고
    • Sunitinib for Asian patients with advanced renal cell carcinoma: A comparable efficacy with different toxicity profiles
    • 21829041 10.1159/000330361 1:CAS:528:DC%2BC3MXhtFCls7fK
    • Kim HS, Hong MH, Kim K, Shin SJ, Ahn JB, Jeung HC, Chung HC, Koh Y, Lee SH, Bang YJ, Rha SY (2011) Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology 80:395-405
    • (2011) Oncology , vol.80 , pp. 395-405
    • Kim, H.S.1    Hong, M.H.2    Kim, K.3    Shin, S.J.4    Ahn, J.B.5    Jeung, H.C.6    Chung, H.C.7    Koh, Y.8    Lee, S.H.9    Bang, Y.J.10    Rha, S.Y.11
  • 8
    • 77953789493 scopus 로고    scopus 로고
    • Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: A single cancer center experience in Korea
    • 19707503 10.4143/crt.2009.41.2.67
    • Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ, Ahn JB, Chung HC, Rha SY (2009) Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat 41:67-72
    • (2009) Cancer Res Treat , vol.41 , pp. 67-72
    • Hong, M.H.1    Kim, H.S.2    Kim, C.3    Ahn, J.R.4    Chon, H.J.5    Shin, S.J.6    Ahn, J.B.7    Chung, H.C.8    Rha, S.Y.9
  • 10
    • 78549246206 scopus 로고    scopus 로고
    • Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
    • Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Y, Ueda E, Ohtsu A (2010) Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs 28:866-875
    • (2010) Invest New Drugs , vol.28 , pp. 866-875
    • Shirao, K.1    Nishida, T.2    Doi, T.3    Komatsu, Y.4    Muro, K.5    Li, Y.6    Ueda, E.7    Ohtsu, A.8
  • 11
    • 34548598185 scopus 로고    scopus 로고
    • Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors
    • 17285315 10.1007/s00280-007-0427-6 1:CAS:528:DC%2BD2sXhtVWqtbfO
    • Guo F, Letrent SP, Sharma A (2007) Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors. Cancer Chemother Pharmacol 60:799-809
    • (2007) Cancer Chemother Pharmacol , vol.60 , pp. 799-809
    • Guo, F.1    Letrent, S.P.2    Sharma, A.3
  • 12
    • 36048936308 scopus 로고    scopus 로고
    • Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese
    • 17947717 10.1200/JCO.2007.11.2938 1:CAS:528:DC%2BD2sXhtlCgsLjJ
    • Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, Baker SD (2007) Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25:4707-4713
    • (2007) J Clin Oncol , vol.25 , pp. 4707-4713
    • Sparreboom, A.1    Wolff, A.C.2    Mathijssen, R.H.3    Chatelut, E.4    Rowinsky, E.K.5    Verweij, J.6    Baker, S.D.7
  • 13
    • 65249087328 scopus 로고    scopus 로고
    • A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients
    • 19258444 10.1158/1078-0432.CCR-08-1893 1:CAS:528:DC%2BD1MXjvVWksLg%3D
    • Houk BE, Bello CL, Kang D, Amantea M (2009) A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 15:2497-2506
    • (2009) Clin Cancer Res , vol.15 , pp. 2497-2506
    • Houk, B.E.1    Bello, C.L.2    Kang, D.3    Amantea, M.4
  • 16
    • 20444393495 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitor resistance in cancer: Role of ABC multidrug transporters
    • 15939339 10.1016/j.drup.2005.02.002
    • Ozvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B (2005) Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist Updat 8:15-26
    • (2005) Drug Resist Updat , vol.8 , pp. 15-26
    • Ozvegy-Laczka, C.1    Cserepes, J.2    Elkind, N.B.3    Sarkadi, B.4
  • 18
    • 25144450089 scopus 로고    scopus 로고
    • Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps
    • 15970668 10.4161/cbt.4.7.1826 1:CAS:528:DC%2BD28XjtlWktLc%3D
    • Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K (2005) Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 4:747-752
    • (2005) Cancer Biol Ther , vol.4 , pp. 747-752
    • Burger, H.1    Van Tol, H.2    Brok, M.3    Wiemer, E.A.4    De Bruijn, E.A.5    Guetens, G.6    De Boeck, G.7    Sparreboom, A.8    Verweij, J.9    Nooter, K.10
  • 19
    • 23044449295 scopus 로고    scopus 로고
    • Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein
    • 16061679 10.1158/0008-5472.CAN-05-0641 1:CAS:528:DC%2BD2MXmvFSlurk%3D
    • Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J, Yang PC (2005) Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 65:6943-6949
    • (2005) Cancer Res , vol.65 , pp. 6943-6949
    • Yang, C.H.1    Huang, C.J.2    Yang, C.S.3    Chu, Y.C.4    Cheng, A.L.5    Whang-Peng, J.6    Yang, P.C.7
  • 22
    • 40349098162 scopus 로고    scopus 로고
    • Drug transporters: Recent advances concerning BCRP and tyrosine kinase inhibitors
    • 18253130 10.1038/sj.bjc.6604213 1:CAS:528:DC%2BD1cXivVOgt7o%3D
    • Lemos C, Jansen G, Peters GJ (2008) Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br J Cancer 98:857-862
    • (2008) Br J Cancer , vol.98 , pp. 857-862
    • Lemos, C.1    Jansen, G.2    Peters, G.J.3
  • 23
    • 70649110001 scopus 로고    scopus 로고
    • Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin
    • 19842935 10.2217/pgs.09.85 1:CAS:528:DC%2BD1MXht12msbrN
    • Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M (2009) Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10:1617-1624
    • (2009) Pharmacogenomics , vol.10 , pp. 1617-1624
    • Keskitalo, J.E.1    Pasanen, M.K.2    Neuvonen, P.J.3    Niemi, M.4
  • 25
    • 78449308869 scopus 로고    scopus 로고
    • ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: Analysis and a comprehensive comparison with other populations
    • 21054463 10.1111/j.1365-2710.2009.01127.x
    • Kim KA, Joo HJ, Park JY (2010) ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations. J Clin Pharm Ther 35:705-712
    • (2010) J Clin Pharm Ther , vol.35 , pp. 705-712
    • Kim, K.A.1    Joo, H.J.2    Park, J.Y.3
  • 26
    • 1442290393 scopus 로고    scopus 로고
    • Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
    • 14752067 10.1200/JCO.2004.06.132
    • Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-463
    • (2004) J Clin Oncol , vol.22 , pp. 454-463
    • Motzer, R.J.1    Bacik, J.2    Schwartz, L.H.3    Reuter, V.4    Russo, P.5    Marion, S.6    Mazumdar, M.7
  • 27
    • 13444269543 scopus 로고    scopus 로고
    • Haploview: Analysis and visualization of LD and haplotype maps
    • 15297300 10.1093/bioinformatics/bth457 1:CAS:528:DC%2BD2MXkt1WitQ%3D%3D
    • Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265
    • (2005) Bioinformatics , vol.21 , pp. 263-265
    • Barrett, J.C.1    Fry, B.2    Maller, J.3    Daly, M.J.4
  • 28
    • 77953967726 scopus 로고    scopus 로고
    • ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma
    • 20348146 10.1093/annonc/mdq150 1:STN:280:DC%2BC3czmtFSjsA%3D%3D
    • Mizuno T, Terada T, Kamba T, Fukudo M, Katsura T, Nakamura E, Ogawa O, Inui K (2010) ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann Oncol 21:1382-1383
    • (2010) Ann Oncol , vol.21 , pp. 1382-1383
    • Mizuno, T.1    Terada, T.2    Kamba, T.3    Fukudo, M.4    Katsura, T.5    Nakamura, E.6    Ogawa, O.7    Inui, K.8
  • 29
    • 65249087328 scopus 로고    scopus 로고
    • A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients
    • 19258444 10.1158/1078-0432.CCR-08-1893 1:CAS:528:DC%2BD1MXjvVWksLg%3D
    • Houk BE, Bello CL, Kang D, Amantea M (2009) A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 15:2497-2506
    • (2009) Clin Cancer Res , vol.15 , pp. 2497-2506
    • Houk, B.E.1    Bello, C.L.2    Kang, D.3    Amantea, M.4
  • 30
    • 59649129538 scopus 로고    scopus 로고
    • Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2
    • 18971320 10.1124/dmd.108.024612 1:CAS:528:DC%2BD1MXhs1Krsbo%3D
    • Shukla S, Robey RW, Bates SE, Ambudkar SV (2009) Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 37:359-365
    • (2009) Drug Metab Dispos , vol.37 , pp. 359-365
    • Shukla, S.1    Robey, R.W.2    Bates, S.E.3    Ambudkar, S.V.4
  • 31
    • 0036598543 scopus 로고    scopus 로고
    • C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance
    • 12479221 1:CAS:528:DC%2BD38XlsFSlsr4%3D
    • Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1:611-616
    • (2002) Mol Cancer Ther , vol.1 , pp. 611-616
    • Imai, Y.1    Nakane, M.2    Kage, K.3    Tsukahara, S.4    Ishikawa, E.5    Tsuruo, T.6    Miki, Y.7    Sugimoto, Y.8
  • 33
    • 34547779489 scopus 로고    scopus 로고
    • Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins
    • 17605814 10.1186/1479-5876-5-32
    • Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5:32
    • (2007) J Transl Med , vol.5 , pp. 32
    • Deprimo, S.E.1    Bello, C.L.2    Smeraglia, J.3    Baum, C.M.4    Spinella, D.5    Rini, B.I.6    Michaelson, M.D.7    Motzer, R.J.8
  • 36
    • 77951093888 scopus 로고    scopus 로고
    • Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib
    • 20147887 10.1038/ki.2009.552 1:CAS:528:DC%2BC3cXkvVGhtr8%3D
    • Porta C, Paglino C, De Amici M, Quaglini S, Sacchi L, Imarisio I, Canipari C (2010) Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 77:809-815
    • (2010) Kidney Int , vol.77 , pp. 809-815
    • Porta, C.1    Paglino, C.2    De Amici, M.3    Quaglini, S.4    Sacchi, L.5    Imarisio, I.6    Canipari, C.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.